



Please type a plus sign (+) inside this box → ☐

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

TRANSMITTAL FORM (to be used for all correspondence after initial filing)		Application Number	09/301,380
		Filing Date	June 15, 2001
		First Named Inventor	Murphy, Gerald P.
		Group Art Unit	1635
		Examiner Name	M. Schmidt
Total Number of Pages in This Submission	one	Attorney Docket Number	20093A002100

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment / Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Postcard
Remarks		The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm and Individual name	Townsend and Townsend and Crew LLP Brian W. Poor		Reg No. 32,928
Signature			
Date	September 28, 2001		

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: September 28, 2001			
Typed or printed name	Jennifer M. Smolen		
Signature		Date	September 28, 2001

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
SE 5010257 v1

1635

TECH CENTER 1500 12900

OCT 04 2001

RECEIVED

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Asst. Commissioner for Patents, Washington, D.C. 20231 on September 28, 2001

By [Signature]

RECEIVED

OCT 04 2001

TECH CENTER 1600/2900

PATENT

Attorney Docket No. 20093A-002100US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of:

GERALD P. MURPHY et al.

Application No.: 09/301,380

Filed: June 15, 2001

For: NR-CAM GENE, NUCLEIC ACIDS
AND NUCLEIC ACID PRODUCTS
FOR THERAPEUTIC AND
DIAGNOSTIC USES FOR
TUMORS

Examiner: M. Schmidt

Art Unit: 1635

**RESPONSE TO RESTRICTION
REQUIREMENT**

#15/
K.T.
10/10

ELECTION

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

This communication is submitted in response to the Restriction Requirement dated August 28, 2001.

RESTRICTION REQUIREMENT:

The Examiner stated that the following groups of claims are subject to restriction:

I. Claims 1, 3-13, 16-17 and 19, drawn to pharmaceutical compositions comprising antisense, methods of treatment using antisense and kits comprising antisense or primers which hybridize to Nr-CAM, classifiable in classes 514 and 536;

II. Claims 1-10, 12-23, 16 and 18-19, drawn to pharmaceutical compositions comprising antibodies or analogs or analogs/derivatives which bind Nr-CAM, methods of treatment using antibodies and kits comprising antibodies to Nr-CAM, classifiable in classes 514 and 530;

III. Claims 3-10, 12-13 and 19, drawn to methods of treatment with nucleic acids comprising a portion of the Nr-CAM gene into which a heterologous sequence has been inserted for the purposes of recombination in to the Nr-CAM gene, thus inhibiting the Nr-CAM gene, classifiable in class 514;